Radioimaging of melanoma using 99mTc-labeled Fab fragment reactive with a high molecular weight melanoma antigen

L. M. Lamki, A. A. Zukiwski, L. J. Shanken, S. S. Legha, R. S. Benjamin, C. E. Plager, D. F. Salk, R. W. Schroff, J. L. Murray

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Twenty patients with metastatic malignant melanoma were studied with 99mTc-labeled monoclonal antibody (MoAb) Fab fragment (NR-MI-05) reactive with a high molecular weight (M(r) 240,000) melanoma associated antigen. Patients received 40 mg unlabeled irrelevant MoAb (NR-2AD-IgG) and 7.5 mg unlabeled NR-Ml-05 (whole IgG) prior to infusion of 10 mg99mTc-labeled (10-25 mCi) NR-Ml-05 Fab. Unlabeled MoAb were given to block nonspecific and specific binding sites. Gamma camera scans and single photon emission computed tomography were performed at 8 and 24 h postadministration. Of 172 preexisting lesions, 136 were imaged for a sensitivity of detection of 79%. Imaging was site and size dependent with the greatest sensitivity for liver lesions (100%) and the least for bowel (0%). Six sites (2 skin, 1 lung, 3 liver) were detected by single photon emission computed tomography that were missed on routine planar images. Forty-one additional unconfirmed sites were seen. Of these, 7 (17%) have been confirmed as tumor after a median follow-up time of 6 months. False positive scans included scar tissue, areas of chronic inflammation, an infected femoral aneurysm, and septic emboli. Nonspecific uptake of radioactivity occurred in kidney, gallbladder, bowel, thyroid, and myocardium. Human anti-mouse antibodies were detected in up to 69% of patients. In summary, radioimaging with 99mTc-NR-Ml-05 is a sensitive test, especially for detecting liver lesions. It is safe, simple to administer, and convenient for the patient. Biodistribution and imaging sensitivity differ significantly from studies in which 111In-labeled anti-melanoma MoAb have been used.

Original languageEnglish
JournalCancer Research
Volume50
Issue number3 SUPPL.
Publication statusPublished - 1990

Fingerprint

Melanoma-Specific Antigens
Immunoglobulin Fab Fragments
Melanoma
Molecular Weight
Monoclonal Antibodies
Single-Photon Emission-Computed Tomography
Liver
Immunoglobulin G
Infected Aneurysm
Immunoglobulin Fragments
Gamma Cameras
Thigh
Gallbladder
Embolism
Radioactivity
Cicatrix
Anti-Idiotypic Antibodies
Myocardium
Thyroid Gland
Binding Sites

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Lamki, L. M., Zukiwski, A. A., Shanken, L. J., Legha, S. S., Benjamin, R. S., Plager, C. E., ... Murray, J. L. (1990). Radioimaging of melanoma using 99mTc-labeled Fab fragment reactive with a high molecular weight melanoma antigen. Cancer Research, 50(3 SUPPL.).

Radioimaging of melanoma using 99mTc-labeled Fab fragment reactive with a high molecular weight melanoma antigen. / Lamki, L. M.; Zukiwski, A. A.; Shanken, L. J.; Legha, S. S.; Benjamin, R. S.; Plager, C. E.; Salk, D. F.; Schroff, R. W.; Murray, J. L.

In: Cancer Research, Vol. 50, No. 3 SUPPL., 1990.

Research output: Contribution to journalArticle

Lamki, LM, Zukiwski, AA, Shanken, LJ, Legha, SS, Benjamin, RS, Plager, CE, Salk, DF, Schroff, RW & Murray, JL 1990, 'Radioimaging of melanoma using 99mTc-labeled Fab fragment reactive with a high molecular weight melanoma antigen', Cancer Research, vol. 50, no. 3 SUPPL..
Lamki, L. M. ; Zukiwski, A. A. ; Shanken, L. J. ; Legha, S. S. ; Benjamin, R. S. ; Plager, C. E. ; Salk, D. F. ; Schroff, R. W. ; Murray, J. L. / Radioimaging of melanoma using 99mTc-labeled Fab fragment reactive with a high molecular weight melanoma antigen. In: Cancer Research. 1990 ; Vol. 50, No. 3 SUPPL.
@article{2c922ad913fa4ed3809d8aac0a4c70cc,
title = "Radioimaging of melanoma using 99mTc-labeled Fab fragment reactive with a high molecular weight melanoma antigen",
abstract = "Twenty patients with metastatic malignant melanoma were studied with 99mTc-labeled monoclonal antibody (MoAb) Fab fragment (NR-MI-05) reactive with a high molecular weight (M(r) 240,000) melanoma associated antigen. Patients received 40 mg unlabeled irrelevant MoAb (NR-2AD-IgG) and 7.5 mg unlabeled NR-Ml-05 (whole IgG) prior to infusion of 10 mg99mTc-labeled (10-25 mCi) NR-Ml-05 Fab. Unlabeled MoAb were given to block nonspecific and specific binding sites. Gamma camera scans and single photon emission computed tomography were performed at 8 and 24 h postadministration. Of 172 preexisting lesions, 136 were imaged for a sensitivity of detection of 79{\%}. Imaging was site and size dependent with the greatest sensitivity for liver lesions (100{\%}) and the least for bowel (0{\%}). Six sites (2 skin, 1 lung, 3 liver) were detected by single photon emission computed tomography that were missed on routine planar images. Forty-one additional unconfirmed sites were seen. Of these, 7 (17{\%}) have been confirmed as tumor after a median follow-up time of 6 months. False positive scans included scar tissue, areas of chronic inflammation, an infected femoral aneurysm, and septic emboli. Nonspecific uptake of radioactivity occurred in kidney, gallbladder, bowel, thyroid, and myocardium. Human anti-mouse antibodies were detected in up to 69{\%} of patients. In summary, radioimaging with 99mTc-NR-Ml-05 is a sensitive test, especially for detecting liver lesions. It is safe, simple to administer, and convenient for the patient. Biodistribution and imaging sensitivity differ significantly from studies in which 111In-labeled anti-melanoma MoAb have been used.",
author = "Lamki, {L. M.} and Zukiwski, {A. A.} and Shanken, {L. J.} and Legha, {S. S.} and Benjamin, {R. S.} and Plager, {C. E.} and Salk, {D. F.} and Schroff, {R. W.} and Murray, {J. L.}",
year = "1990",
language = "English",
volume = "50",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "3 SUPPL.",

}

TY - JOUR

T1 - Radioimaging of melanoma using 99mTc-labeled Fab fragment reactive with a high molecular weight melanoma antigen

AU - Lamki, L. M.

AU - Zukiwski, A. A.

AU - Shanken, L. J.

AU - Legha, S. S.

AU - Benjamin, R. S.

AU - Plager, C. E.

AU - Salk, D. F.

AU - Schroff, R. W.

AU - Murray, J. L.

PY - 1990

Y1 - 1990

N2 - Twenty patients with metastatic malignant melanoma were studied with 99mTc-labeled monoclonal antibody (MoAb) Fab fragment (NR-MI-05) reactive with a high molecular weight (M(r) 240,000) melanoma associated antigen. Patients received 40 mg unlabeled irrelevant MoAb (NR-2AD-IgG) and 7.5 mg unlabeled NR-Ml-05 (whole IgG) prior to infusion of 10 mg99mTc-labeled (10-25 mCi) NR-Ml-05 Fab. Unlabeled MoAb were given to block nonspecific and specific binding sites. Gamma camera scans and single photon emission computed tomography were performed at 8 and 24 h postadministration. Of 172 preexisting lesions, 136 were imaged for a sensitivity of detection of 79%. Imaging was site and size dependent with the greatest sensitivity for liver lesions (100%) and the least for bowel (0%). Six sites (2 skin, 1 lung, 3 liver) were detected by single photon emission computed tomography that were missed on routine planar images. Forty-one additional unconfirmed sites were seen. Of these, 7 (17%) have been confirmed as tumor after a median follow-up time of 6 months. False positive scans included scar tissue, areas of chronic inflammation, an infected femoral aneurysm, and septic emboli. Nonspecific uptake of radioactivity occurred in kidney, gallbladder, bowel, thyroid, and myocardium. Human anti-mouse antibodies were detected in up to 69% of patients. In summary, radioimaging with 99mTc-NR-Ml-05 is a sensitive test, especially for detecting liver lesions. It is safe, simple to administer, and convenient for the patient. Biodistribution and imaging sensitivity differ significantly from studies in which 111In-labeled anti-melanoma MoAb have been used.

AB - Twenty patients with metastatic malignant melanoma were studied with 99mTc-labeled monoclonal antibody (MoAb) Fab fragment (NR-MI-05) reactive with a high molecular weight (M(r) 240,000) melanoma associated antigen. Patients received 40 mg unlabeled irrelevant MoAb (NR-2AD-IgG) and 7.5 mg unlabeled NR-Ml-05 (whole IgG) prior to infusion of 10 mg99mTc-labeled (10-25 mCi) NR-Ml-05 Fab. Unlabeled MoAb were given to block nonspecific and specific binding sites. Gamma camera scans and single photon emission computed tomography were performed at 8 and 24 h postadministration. Of 172 preexisting lesions, 136 were imaged for a sensitivity of detection of 79%. Imaging was site and size dependent with the greatest sensitivity for liver lesions (100%) and the least for bowel (0%). Six sites (2 skin, 1 lung, 3 liver) were detected by single photon emission computed tomography that were missed on routine planar images. Forty-one additional unconfirmed sites were seen. Of these, 7 (17%) have been confirmed as tumor after a median follow-up time of 6 months. False positive scans included scar tissue, areas of chronic inflammation, an infected femoral aneurysm, and septic emboli. Nonspecific uptake of radioactivity occurred in kidney, gallbladder, bowel, thyroid, and myocardium. Human anti-mouse antibodies were detected in up to 69% of patients. In summary, radioimaging with 99mTc-NR-Ml-05 is a sensitive test, especially for detecting liver lesions. It is safe, simple to administer, and convenient for the patient. Biodistribution and imaging sensitivity differ significantly from studies in which 111In-labeled anti-melanoma MoAb have been used.

UR - http://www.scopus.com/inward/record.url?scp=0025192246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025192246&partnerID=8YFLogxK

M3 - Article

C2 - 2297740

AN - SCOPUS:0025192246

VL - 50

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 3 SUPPL.

ER -